Venclexta
Maximizing the Benefit of Venetoclax in AML
The approval of venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine provides ...
AUGUST 23, 2021
Venclexta Approved for Treatment of Previously Untreated CLL/SLL
The FDA approved venetoclax (Venclexta, AbbVie/Genentech) for the treatment of adults with chronic lymphocytic ...
JUNE 4, 2019
FDA Halts MM Trial, Deaths Seen in Venclexta Arm
The FDA halted a clinical trial of Venclexta for MM because of an increased risk for death; does not affect ...
MARCH 26, 2019
FDA Approves New Options for AML
The FDA approved two additional treatment options for older patients with AML and patients who are unable to ...
DECEMBER 14, 2018
FDA Approves Venetoclax Combinations for Adults With AML
The FDA granted accelerated approval to venetoclax (Venclexta, AbbVie/Genentech) for use in combination with ...
NOVEMBER 29, 2018
Venclexta Approved for CLL/SLL After 1 Prior Therapy
The FDA granted regular approval to venetoclax (Venclexta, AbbVie/Genentech) in patients with chronic ...
JUNE 18, 2018
FDA Grants Breakthrough Designation to Venclexta for AML
Venetoclax was granted breakthrough designation for use in combination with low-dose cytarabine for older patients ...
JULY 31, 2017